Intradermal vaccination of adults with three low doses (2 µg) of recombinant hepatitis B vaccine. I: seroconversion rate and adverse effects
Mem. Inst. Oswaldo Cruz
; 98(8): 1101-1107, Dec. 2003. tab, graf
Artigo
em Inglês
| LILACS
| ID: lil-355753
Biblioteca responsável:
BR1.1
ABSTRACT
A total of 250 dentists (53.6 percent men and 46.4 percent women), with a mean age of 35.1 ± 9.8 years, were submitted to serological tests for the diagnosis of hepatitis B (HB) - HBsAg, anti-HBs, anti-HBc, HBeAg, and anti-HBe - using a radioimmunoassay. One or more of these markers were detected in 78 individuals (31.2 percent) who were excluded from the group to be vaccinated. Of the 172 HB-susceptible individuals, 135 (78.5 percent) responded to the call and were intradermally injected with three 2 µg doses of the Belgian HB recombinant vaccine, applied at an interval of one month between the 1st and 2nd dose and of five months between the 2nd and 3rd dose. A new determination of HB markers carried out 50 days after the 3rd dose showed that 110 (81.5 percent) individuals had become anti-HBs positive (65.5 percent good responders and 34.5 percent poor responders). Mean serum anti-HBs titer of these 110 dentists was 42.4 U S/N, similar in both sexes. The adverse effects analyzed in 106 dentists were (a) local pain (12.3 percent), burning sensation (14.1 percent), pruritus (25.5 percent), erythema (28.3 percent), local heat (18.9 percent), and a hypochromic spot (32.1 percent); (b) systemic (4.7 percent) discomfort in two patients, and fever, anorexia, and asthenia in one patient each. Intradermal administration of a fourth 2 µg vaccine dose to 39 dentists (poor or non-responders) increased the total number of anti-HBs-positive individuals from 110 (81.5 percent) to 114 (84.4 percent), with the number of good responders increasing from 72 (65.5 percent) to 85 (74.6 percent). We conclude that the Belgian recombinant vaccine applied in the scheme used here induces a high rate of seroconversion and causes only mild and transitory adverse effects.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
Problema de saúde:
Meta 3.3: Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
Base de dados:
LILACS
Assunto principal:
Vírus da Hepatite B
/
Vacinas contra Hepatite B
/
Hepatite B
/
Anticorpos Anti-Hepatite B
/
Memória Imunológica
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Mem. Inst. Oswaldo Cruz
Assunto da revista:
Medicina Tropical
/
Parasitologia
Ano de publicação:
2003
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Associação Odontológica do Norte do Paraná/BR
/
Universidade Estadual de Londrina/BR
/
Universidade Federal de Minas Gerais/BR